Ppv 3125926 |work| ❲2027❳

: Denotes the platform and the payment model (one-time purchase for access).

| Metric | Value (95% CI) | |----------------------------|---------------------| | Positive Predictive Value | 78.4% (74.1–82.3) | | Negative Predictive Value | 79.2% (75.0–83.0) | | Sensitivity | 84.5% (80.3–88.1) | | Specificity | 72.1% (68.4–75.6) |

: For a comprehensive and accurate report on PPV 3125926, accessing a patent database such as Google Patents, USPTO (United States Patent and Trademark Office), or Espacenet would be essential. Without specific details on the invention, the report remains speculative.

While this is a patent document and not a traditional academic journal paper, patent documents are technical disclosures often cited in engineering and computer science literature. Below is the bibliographic information and abstract for this technical disclosure.

Early detection of metabolic syndrome (MetS) in low-resource settings remains challenging. The positive predictive value (PPV) of simplified screening tools is often unknown. Methods: We conducted a cross-sectional validation study (ID: PPV-3125926) enrolling 1,200 adults from six rural communities. A novel 3-item screening questionnaire (abdominal obesity, hypertension history, fasting glucose >100 mg/dL) was compared against the IDF/NHLBI criteria. Results: Prevalence of MetS was 31.2%. The screening tool’s PPV was 78.4% (95% CI: 74.1–82.3), with sensitivity 84.5% and specificity 72.1%. Conclusion: The PPV-3125926 protocol offers acceptable performance for population-based screening in rural settings.